Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
MODERNA, INC. |
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 79.45 USD | +1.62% | +1.43% | -55.86% | |
| 03:10pm | Generation Bio to Lay Off 40% of Staff in Bid to Extend Cash Runway Into H2 2027 | MT |
| 01:34pm | Canaccord Genuity Starts Moderna With Hold Rating, Price Target is $82 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
Financials (USD)
| Sales 2023 * | 6,493 M | Sales 2024 * | 4,511 M | Capitalization | 29.81 B |
|---|---|---|---|---|---|
| Net income 2023 * | -5,412 M | Net income 2024 * | -2,319 M | EV / Sales 2023 * | 3,77x |
| Net cash position 2023 * | 5,347 M | Net cash position 2024 * | 3,795 M | EV / Sales 2024 * | 5,77x |
| P/E ratio 2023 * | -5,69x | P/E ratio 2024 * | -12,8x | Employees | 3,900 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 90.37% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +2.05% | ||
| 1 week | +2.06% | ||
| Current month | +5.03% | ||
| 1 month | +7.71% | ||
| 3 months | -31.22% | ||
| 6 months | -38.10% | ||
| Current year | -55.58% |
1 week
75.66
81.12
1 month
62.5581.12
Current year
62.55207.51
1 year
62.55217.25
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 50 | 2011 |
James Mock
DFI | Director of Finance/CFO | 46 | 2022 |
Stephen Hoge
PSD | President | 47 | 2012 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 64 | 2018 |
| Director/Board Member | 73 | 2020 | |
Francois Nader
BRD | Director/Board Member | 66 | 2019 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.10% | 5 M€ | -19.87% | ||
| 5.66% | 0 M€ | 0.00% | - | |
| 5.54% | 12 M€ | -21.64% | ||
| 4.69% | 2 M€ | 0.00% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-29 | 79.22 | +1.33% | 1 352 210 |
| 23-11-28 | 78.18 | +0.59% | 2,240,038 |
| 23-11-27 | 77.72 | -1.02% | 2,960,110 |
| 23-11-24 | 78.52 | +0.45% | 2,152,974 |
| 23-11-22 | 78.17 | +1.34% | 2,203,917 |
Delayed Quote Nasdaq, November 29, 2023 at 09:39 am EST
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2023-11-30
- Piper Sandler Healthcare Conference
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
78.18USD
Average target price
139.90USD
Spread / Average Target
+78.95%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -55.58% | 29 809 M $ | |
| +66.84% | 40 404 M $ | |
| +4.35% | 38 508 M $ | |
| -24.52% | 28 695 M $ | |
| +38.20% | 22 029 M $ | |
| -31.26% | 20 250 M $ | |
| +2.80% | 17 781 M $ | |
| -16.76% | 10 827 M $ | |
| -9.34% | 10 014 M $ | |
| -24.53% | 9 752 M $ |